

美時公告 8 月自結合併營收約新台幣 6.3 億 年增 20.4%

*Lotus Unaudited August Revenues Reached NT\$627Million, A 20.4% Increase Over Previous Year*

2019 年 9 月 10 日，台北

September 10<sup>th</sup>, 2019, Taipei

特殊學名藥廠美時化學製藥（以下簡稱「美時」，台灣櫃買中心股票代碼：1795）公佈 2019 年 8 月自結合併營收為新台幣 627,033 仟元，較去年同期增加 20%，累計年增 31%。美時表示海外子公司營收月減 27% 為波動主因，主係七月韓國女性保健產品線新經銷商一次性拉貨造成前月基期較高、部分韓國 B2B 客戶訂單遞延以及因預備第四季時減肥新藥 Qsymia 之上市，通路對前一代減肥藥物如 Phentermine 及 Phendimetrazine 的拉貨消退；然因銷往美國之戒癮含片主流劑量 8mg/2mg 於八月放量，戒癮含片營收較上月增加 45%，故母公司之台灣本地與外銷業務較上月成長約 9%

*Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, TPEX ticker: 1795) today announced that its consolidated sales for August 2019 amounted to NT\$627,033 thousand, representing approximately 20% growth over same period last year and a 31% increase year-to-date. Comparing to the month of July, revenue contributed by overseas subsidiaries reduced by 27%, which is mainly explained by a) absent of large stock-up order in July due to the change of distributor in Korea women health flagship product Mercilon, b) timing of shipment to Korea B2B customers, and c) channels destocking last generation anti-obesity products in Korea such as Phentermine and Phendimetrazine, in the wake of Qsymia approval. Lotus Taiwan parent company revenues increased 9.3%, comparing to the previous month, mainly contributed by approximately 45% increase in sales in the US opioid usage disorder product Buprenorphine / Naloxone film as mainstream strength 8mg/2mg picked up.*

**新聞聯繫人 Contact:**

美時製藥 投資人關係經理 陳荻雅 (02)2700 5908 investor@lotuspharm.com

**Nadiya Chen, Investor Relations Manager**

**關於美時：**

美時化學製藥股份有限公司（股票代碼：1795）成立於 1966 年，為一以台灣為基地供應全球市場之學名藥廠，高價值產品線涵蓋中樞神經系統、心血管疾病、癌症、女性保健、減肥等，並以錠劑、膠囊及軟膠囊劑型為主；美時自 2014 年成為艾威群集團的一員，現專注於快速成長的抗癌市場，並矢志透過整合台灣與韓國首屈一指的研發平台與其製造優勢嘉惠病患、員工與股東。美時的行銷與業務

通路包含直營的亞洲市場及艾威群集團橫跨全球超過 30 個國家的商業網絡，此外，美時亦積極與一線藥廠就產品線策略結盟，是少數能進軍所有市場的新興藥廠。

### **About Lotus**

*Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company's internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company's direct markets, relationship with Alvogen's commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.*

#### 聲明：

本文件及同時發佈之相關資訊內含有預測性敘述。除針對已發生事實，所有對美時製藥(以下簡稱本公司)未來經營業務、可能發生之事件及展望(包括但不限於預測、目標、估算和營運計劃)之敘述皆屬預測性敘述。預測性敘述會受不同因素及不確定性的影響，造成與實際情況有相當差異，這些因素包括但不限於價格波動、實際需求、匯率變動、市占率、市場競爭情況，法律、金融及法規架構的改變、國際經濟暨金融市場情勢、政治風險、成本估計等，及其他本公司控制範圍以外的風險與變數。這些預測性敘述是基於現況的預測和評估，本公司不負日後更新之責。